ESC 365 - Secondary cardiovascular disease prevention: what have we learnt from recent clinical trials?

Open Access

Secondary cardiovascular disease prevention: what have we learnt from recent clinical trials?

Session: Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol

Topic: Atherosclerosis

Speaker: Doctor P. Ridker (Boston, US)

Sponsored by Novartis Pharma AG

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Paul M Ridker

Brigham and Women's Hospital, Boston (United States of America)

37 presentations

7 followers

6 more presentations in this session

Welcome - Atherosclerosis and secondary cardiovascular disease prevention: inflammation and LDL-cholesterol.

Speaker: Professor T. Luescher (London, GB)

Atherosclerosis and the cardiovascular continuum.

Speaker: Professor P. Libby (Boston, US)

What are the unmet medical needs in secondary cardiovascular disease prevention?

Speaker: Professor P. Steg (Paris, FR)

Cardiovascular residual risk: what are the markers?

Speaker: Professor W. Koenig (Munich, DE)

Audience Q&A and panel discussion - Atherosclerosis and secondary cardiovascular disease prevention: inflammation and LDL-cholesterol.

Speaker: Professor P. Libby (Boston, US)

Access the full session

Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol

Speakers: Doctor P. Ridker, Professor T. Luescher, Professor P. Libby, Professor P. Steg, Professor W. Koenig...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources